

**WHAT IS CLAIMED IS:**

1                   1.       A method for treating an inflammatory disease or reducing an  
2 inflammatory reaction, said method comprising: administering a SOC inhibitor, thereby  
3 treating said inflammatory disease or reducing said inflammatory reaction.

1                   2.       The method of claim 1, wherein said inflammatory disease or  
2 inflammatory reaction is a skin disorder.

1                   3.       The method of claim 2, wherein said skin disorder is selected from the  
2 group consisting of atopic dermatitis, psoriasis, neurogenic inflammation, skin photodamage,  
3 a cell carcinoma, keratosis, and a disorder of keratinization.

1                   4.       The method of claim 1, wherein said inflammatory disease or  
2 inflammatory reaction is an inflammatory pulmonary disease or reaction.

1                   5.       The method of claim 4, wherein said inflammatory pulmonary disease  
2 or reaction is selected from the group consisting of asthma, allergic rhinitis, chronic  
3 obstructive pulmonary disease and adult respiratory distress syndrome.

1                   6.       The method of claim 1, wherein said inflammatory disease or  
2 inflammatory reaction is an inflammatory musculoskeletal disease or reaction.

1                   7.       The method of claim 6, wherein said inflammatory musculoskeletal  
2 disease is a member selected from the group consisting of psoriatic arthritis, osteoarthritis,  
3 and osteoporosis.

1                   8.       The method of claim 1, wherein said inflammatory disease or  
2 inflammatory reaction is an inflammatory gastrointestinal or urogenital disease or reaction.


1                   9.       The method of claim 8, wherein said inflammatory gastrointestinal or  
2 urogenital disease or reaction is a member selected from the group consisting of  
3 inflammatory bowel disease, enterocolitis, gastritis, vaginitis, and interstitial cystitis.

1                   10.      The method of claim 1, wherein said inflammatory disease or  
2 inflammatory reaction is an autoimmune disease or reaction.

1                   **11.**     The method of claim 10, wherein said autoimmune disease is a  
2 member selected from the group consisting of multiple sclerosis, type II diabetes, lupus, and  
3 rheumatoid arthritis.

1                   **12.**     The method of claim 1, wherein said inflammatory disease or  
2 inflammatory reaction is transplantation treatment.

1                   **13.**     The method of claim 1, wherein said SOC inhibitor is a compound  
2 having the formula:



3  
4 wherein:


5                   R<sup>1</sup> is a member selected from the group consisting of optionally substituted  
6 alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of  
7 unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
8 substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
9 heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
10 oximinoaryl and optionally substituted heteroarylalkoxy;

11                  R<sup>2</sup> is a member selected from the group consisting of optionally substituted  
12 (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, optionally substituted aryl,  
13 optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
14 substituted heteroarylalkoxy;

15                  R<sup>4</sup> is an optionally substituted alkyl; and

16                  R<sup>5</sup> is an optionally substituted alkyl, or alternatively, R<sup>4</sup> and R<sup>5</sup> and the  
17 carbons to which they are attached, joined to form an optionally substituted aryl or optionally  
18 substituted heteroalkyl 5-or 6 membered ring.

1                   **14.**     The method of claim 13, wherein said compound is a member selected  
2 from the group consisting of




wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkoxy, and optionally substituted; and


$R^2$  is a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy.


15. The method of claim 13, wherein  $R^1$  is an optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation.

16. The method of claim 14, wherein said compound is




17. The method of claim 13, wherein  $R^1$  is a member selected from the group consisting of






10  $\text{R}^3$  is a member selected from the group consisting of consisting of alkyl,  
 11 alkoxysulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl,  
 12 optionally substituted alkylamido, optionally substituted amidino, optionally substituted  
 13 alkylsulfonamido, alkoyloxyamino, alkylaminosulfonamido, and alkoxycarbonyl.

1 18. The method of claim 17, wherein  $\text{R}^3$  is a member selected from the  
 2 group consisting of consisting of




1 19. The method of claim 18, wherein  $\text{R}^2$  is independently a member  
 2 selected from the group consisting of optionally substituted alkoxy, acyl, optionally  
 3 substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and  
 4 optionally substituted heteroarylalkoxy.

20. The method of claim 19, wherein R<sup>2</sup> is a member selected from the group consisting of



21. The method of claim 20, wherein R<sup>2</sup> is p-fluorophenyl.


22. The method of claim 13, wherein said compound has the formula



23. The method of claim 1, wherein said SOC inhibitor is a  $\delta$ -lactone-containing statin.

24. The method of claim 23, wherein said  $\delta$ -lactone-containing statin is a member selected from the group consisting of lovastatin, mevastatin, and simvastatin.

25. A compound having the formula



wherein:


7  
4  $R^1$  is a member selected from the group consisting of optionally substituted  
5 alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of  
6 unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
7 substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
8 heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
9 oximinoaryl and optionally substituted heteroarylalkoxy;

10  $R^2$  is a member selected from the group consisting of optionally substituted  
11  $(C_1-C_6)$ alkyl, optionally substituted  $(C_1-C_6)$ alkoxy, acyl, optionally substituted aryl,  
12 optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
13 substituted heteroarylalkoxy;

14  $R^4$  is an optionally substituted alkyl; and

15  $R^5$  is an optionally substituted alkyl, or alternatively,  $R^4$  and  $R^5$  and the  
16 carbons to which they are attached, joined to form an optionally substituted aryl or optionally  
17 substituted heteroalkyl 5-or 6 membered ring.

1 26. The compound of claim 25, wherein said compound is a member  
2 selected from the group consisting of




4 wherein:

5  $R^1$  is a member selected from the group consisting of optionally substituted  
6 alkyl, optionally substituted alkoxy, optionally substituted  $(C_2-C_{18})$ alkylene having at least 2  
7 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
8 substituted heteroarylalkyl, optionally substituted heteroarylalkoxy, and optionally  
9 substituted; and


10  $R^2$  is a member selected from the group consisting of optionally substituted  
11  $(C_1-C_6)$ alkyl, optionally substituted  $(C_1-C_6)$ alkoxy, acyl, optionally substituted aryl,  
12 optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
13 substituted heteroarylalkoxy.

1 27. The compound of claim 25, wherein  $R^1$  is an optionally substituted  
2  $(C_2-C_{18})$ alkylene having at least 2 sites of unsaturation.

28. The compound of claim 26, wherein said compound is



29. The compound of claim 25, wherein R<sup>1</sup> is a member selected from the group consisting of




R<sup>3</sup> is a member selected from the group consisting of consisting of alkyl, alkoxy sulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl, optionally substituted alkylamido, optionally substituted amidino, optionally substituted alkylsulfonamido, alkoxyloxyamino, alkylaminosulfonamido, and alkoxy carbonyl.


30. The compound of claim 29, wherein R<sup>3</sup> is a member selected from the group consisting of consisting of







35. A compound having the formula



II

wherein:


$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoalkoxy, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^6$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; and

$R^7$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; or alternatively,  $R^6$  and  $R^7$  and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring.

36. The compound of claim 35, wherein said compound is a member selected from the group consisting of





wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; and

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy.

37. The compound of claim 36, wherein  $R^1$  is a member selected from the group consisting of








about 1 to about 14 and  $\text{---}(\text{CH}=\text{CH})_3\text{---R}^3$ ; and  $\text{---}(\text{CH}=\text{CH})_2\text{---}(\text{CH}_2)_x\text{---R}^3$  wherein x is


**R<sup>3</sup> is a member selected from the group consisting of consisting of alkyl, alkoxy sulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl, optionally substituted alkylamido, optionally substituted amidino, optionally substituted alkylsulfonamido, alkoxyl oxyamino, alkylaminosulfonamido, and alkoxycarbonyl.**


38. The compound of claim 37, wherein R<sup>3</sup> is a member selected from the group consisting of consisting of



wherein n is about 1 to about 10 and -CH<sub>3</sub>.


39. The compound of claim 36, wherein R<sup>2</sup> is a member selected from the group consisting of consisting of





1                    40.     The compound of claim 39, wherein R<sup>2</sup> is p-fluorophenyl.

1                    41.     A compound having the formula



2  
3     wherein:


4                    R<sup>1</sup> is a member selected from the group consisting of optionally substituted  
5     alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of  
6     unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
7     substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
8     heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
9     oximinoaryl and optionally substituted heteroarylalkoxy;

10                  R<sup>2</sup> is independently a member selected from the group consisting of optionally  
11     substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, optionally substituted  
12     aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
13     substituted heteroarylalkoxy;

14                  R<sup>8</sup> is a member selected from the group consisting of an optionally substituted  
15     alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted  
16     heteroarylalkyl, and optionally substituted heteroarylalkoxy;

17                  R<sup>9</sup> is a member selected from the group consisting of an optionally substituted  
18     alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted  
19     heteroarylalkyl, and optionally substituted heteroarylalkoxy; or alternatively, R<sup>8</sup> and R<sup>9</sup> and  
20     the carbons to which they are attached, joined to form an optionally substituted aryl or  
21     optionally substituted heteroalkyl 5-or 6 membered ring.

42. The compound of claim 41, wherein said compound is a member selected from the group consisting of





wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkoxy, and optionally substituted; and

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy.

43. The compound of claim 42, wherein  $R^1$  is a member selected from the group consisting of








1 to about 14 and  $\text{---}(\text{CH}=\text{CH})_3\text{---R}^3$ ; and


$R^3$  is a member selected from the group consisting of consisting of alkyl, alkoysulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl, optionally substituted alkylamido, optionally substituted amidino, optionally substituted alkylsulfonamido, alkoyloxyamino, alkylaminosulfonamido, and alkoxycarbonyl.


**44.** The compound of claim 43, wherein R<sup>3</sup> is a member selected from the group consisting of consisting of



wherein n is about 1 to about 10 and -CH<sub>3</sub>.


**45.** The compound of claim **42**, wherein R<sup>2</sup> is a member selected from the group consisting of consisting of





1                    46.     The compound of claim 45, wherein R<sup>2</sup> is p-fluorophenyl.

1                    47.     A compound having the formula




wherein:

R<sup>1</sup> is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroarylminooxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

R<sup>2</sup> is a member selected from the group consisting of optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; and

Q is a member selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkoxy and hydroxy.


1                    48.     The compound of claim 47, wherein R<sup>1</sup> is a member selected from the  
2     group consisting of







50. A compound having the formula



V


wherein:


R<sup>1</sup> is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

R<sup>2</sup> is independently a member selected from the group consisting of optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; and

Q is a member selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkoxy and hydroxy.


51. The compound of claim 50, wherein R<sup>1</sup> is a member selected from the group consisting of






$R^3$  is a member selected from the group consisting of consisting of alkyl, alkoxy sulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl, optionally substituted alkylamido, optionally substituted amidino, optionally substituted alkylsulfonamido, alkoyloxyamino, alkylaminosulfonamido, and alkoxy carbonyl.

**52.** The compound of claim 51, wherein  $R^3$  is a member selected from the group consisting of consisting of



**53.** A pharmaceutical composition, said pharmaceutical composition comprising:

a compound having the formula



wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;


$R^2$  is a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^4$  is an optionally substituted alkyl;

$R^5$  is an optionally substituted alkyl, or alternatively,  $R^4$  and  $R^5$  and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring; and

a pharmaceutically acceptable excipient therefor.

**54.** The pharmaceutical composition of claim 53, wherein said compound is a member selected from the group consisting of



wherein:


$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkoxy, and optionally substituted; and

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy.


**55.** The pharmaceutical composition of claim 54, wherein  $R^1$  is an optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation.

56. The pharmaceutical composition of claim 54, wherein said compound

is





57. The pharmaceutical composition of claim 53, wherein R<sup>1</sup> is a member selected from the group consisting of





R<sup>3</sup> is a member selected from the group consisting of consisting of alkyl, alkoxy sulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl, optionally substituted alkylamido, optionally substituted amidino, optionally substituted alkylsulfonamido, alkoyloxyamino, alkylaminosulfonamido, and alkoxy carbonyl.

58. The pharmaceutical composition of claim 57, wherein R<sup>3</sup> is a member selected from the group consisting of consisting of




3 

4 


5 

95



62. A pharmaceutical composition, said pharmaceutical composition comprising:

a compound having the formula



wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoalkoxy, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

$R^2$  is a member selected from the group consisting of optionally substituted  $(C_1-C_6)$ alkyl, optionally substituted  $(C_1-C_6)$ alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;


$R^6$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^7$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; or alternatively,  $R^6$  and  $R^7$  and

the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring; and  
a pharmaceutically acceptable excipient therefor.

63. A pharmaceutical composition, said pharmaceutical composition comprising:

a compound having the formula



wherein:

R<sup>1</sup> is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;


R<sup>2</sup> is independently a member selected from the group consisting of optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

R<sup>8</sup> is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

R<sup>9</sup> is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkoxy; or alternatively, R<sup>8</sup> and R<sup>9</sup> and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring; and

a pharmaceutically acceptable excipient therefor.

1                    64.     A pharmaceutical composition, said pharmaceutical composition  
2 comprising:  
3                    a compound having the formula



4  
5 wherein:

6                    R¹ is a member selected from the group consisting of optionally substituted  
7 alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of  
8 unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
9 substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
10 heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
11 oximinoaryl and optionally substituted heteroarylalkoxy;


12                    R² is a member selected from the group consisting of optionally substituted  
13 (C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, acyl, optionally substituted aryl,  
14 optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
15 substituted heteroarylalkoxy;

16                    Q is a member selected from the group consisting of hydrogen, optionally  
17 substituted alkyl, optionally substituted alkoxy and hydroxy; and

18                    a pharmaceutically acceptable excipient therefor.

1                    65.     A pharmaceutical composition, said pharmaceutical composition  
2 comprising:

3                    a compound having the formula



4  
5 wherein:

6                    R¹ is a member selected from the group consisting of optionally substituted  
7 alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of




8 unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
9 substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
10 heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
11 oximinoaryl and optionally substituted heteroarylalkoxy;

12  $R^2$  is independently a member selected from the group consisting of optionally  
13 substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted  
14 aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
15 substituted heteroarylalkoxy;

16 Q is a member selected from the group consisting of hydrogen, optionally  
17 substituted alkyl, optionally substituted alkoxy and hydroxy; and  
18 pharmaceutically acceptable excipient therefor.

1 66. A method for blocking calcium influx from the extracellular space,  
2 said method comprising: contacting a cell with a store operated calcium influx (SOC)  
3 inhibitor, thereby blocking calcium influx from the extracellular space.

1 67. The method of claim 66, wherein said SOC inhibitor is a compound  
2 having the formula



3  
4 wherein:


5  $R^1$  is a member selected from the group consisting of optionally substituted  
6 alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of  
7 unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
8 substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
9 heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
10 oximinoaryl and optionally substituted heteroarylalkoxy;

11  $R^2$  is a member selected from the group consisting of optionally substituted  
12 ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl,  
13 optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted  
14 heteroarylalkoxy;

15  $R^4$  is an optionally substituted alkyl; and

$R^5$  is an optionally substituted alkyl, or alternatively,  $R^4$  and  $R^5$  and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring.

68. The method of claim 67, wherein said SOC inhibitor is a compound selected from the group consisting of




wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkoxy, and optionally substituted; and

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy.


69. The method of claim 67, wherein said SOC inhibitor is a compound wherein  $R^1$  is an optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation.

70. The method of claim 68, wherein said compound is




71. The method of claim 67, wherein  $R^1$  is a member selected from the group consisting of


3




4




5




6



7



8



9

about 1 to about 14 and  $-(CH=CH)_3-R^3$ ; and  $-(CH=CH)_2-(CH_2)_x-R^3$  wherein x is

10

11

12

13

$R^3$  is a member selected from the group consisting of alkyl, alkoxy sulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl, optionally substituted alkylamido, optionally substituted amidino, optionally substituted alkylsulfonamido, alkoyloxyamino, alkylaminosulfonamido, and alkoxy carbonyl.


1


2

3

72. The method of claim 71, wherein  $R^3$  is a member selected from the group consisting of


4






1 73. The method of claim 71, wherein R<sup>2</sup> is independently a member  
 2 selected from the group consisting of optionally substituted alkoxy, acyl, optionally  
 3 substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and  
 4 optionally substituted heteroarylalkoxy.


1 74. The method of claim 71, wherein R<sup>2</sup> is a member selected from the  
 2 group consisting of consisting of



1 75. The method of claim 67, wherein said compound has the formula



1                    76.     The method of claim 66, wherein said SOC inhibitor is a compound  
2     having the formula



II

3  
4     wherein:


5                    R¹ is a member selected from the group consisting of optionally substituted  
6     alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of  
7     unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
8     substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
9     heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
10    oximinoaryl and optionally substituted heteroarylalkoxy;

11                   R² is independently a member selected from the group consisting of optionally  
12    substituted (C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, acyl, optionally substituted  
13    aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
14    substituted heteroarylalkoxy;

15                   R⁶ is a member selected from the group consisting of an optionally substituted  
16    alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted  
17    heteroarylalkyl, and optionally substituted heteroarylalkoxy;

18                   R⁷ is a member selected from the group consisting of an optionally substituted  
19    alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted  
20    heteroarylalkyl, and optionally substituted heteroarylalkoxy; or alternatively, R⁶ and R⁷ and  
21    the carbons to which they are attached, joined to form an optionally substituted aryl or  
22    optionally substituted heteroalkyl 5-or 6 membered ring.

1                    77.     The method of claim 66, wherein said SOC inhibitor is a compound  
2     having the formula



III

wherein:


$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^8$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^9$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; or alternatively,  $R^8$  and  $R^9$  and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring.

78. The method of claim 66, wherein said SOC inhibitor is a compound having the formula




wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

11  $R^2$  is a member selected from the group consisting of optionally substituted  
12  $(C_1-C_6)$ alkyl, optionally substituted  $(C_1-C_6)$ alkoxy, acyl, optionally substituted aryl,  
13 optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
14 substituted heteroarylalkoxy; and

15 Q is a member selected from the group consisting of hydrogen, optionally  
16 substituted alkyl, optionally substituted alkoxy and hydroxy.

1 79. The method of claim 66, wherein said SOC inhibitor is a compound  
2 having the formula



3  
4 wherein:

5  $R^1$  is a member selected from the group consisting of optionally substituted  
6 alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of  
7 unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally  
8 substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted  
9 heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted  
10 oximinoaryl and optionally substituted heteroarylalkoxy;

11  $R^2$  is independently a member selected from the group consisting of optionally  
12 substituted  $(C_1-C_6)$ alkyl, optionally substituted  $(C_1-C_6)$ alkoxy, acyl, optionally substituted  
13 aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally  
14 substituted heteroarylalkoxy; and

15 Q is a member selected from the group consisting of hydrogen, optionally  
16 substituted alkyl, optionally substituted alkoxy and hydroxy.

1 80. The method of claim 66, wherein said SOC inhibitor is a  $\delta$ -lactone-  
2 containing statin.

1 81. The method of claim 80, wherein said  $\delta$ -lactone-containing statin is a  
2 member selected from the group consisting of lovastatin, mevastatin, and simvastatin.

1                   **82.**     A method for treating inflammatory bowel disease (IBD), said method  
2 comprising:  
3                   administering a store operated calcium influx (SOC) inhibitor, thereby treating  
4 inflammatory bowel disease (IBD).

1                   **83.**     A method of treating a disease, comprising administering a  
2 pharmaceutical composition comprising an aerosol formulation of a SOC inhibitor, wherein  
3 said disease is selected from the group consisting of acute lung injury, adult respiratory  
4 distress syndrome, asthma, interstitial lung disease, emphysema, chronic bronchitis and cystic  
5 fibrosis.